The ability to improve metabolic plasticity by affecting SRC, glycolytic reserves, glucose oxidation, and FAO such as what we found in SAV1 KD cells may have clinical potential in treating metabolic dysfunction as patients with type 2 diabetes mellitus and obesity often have impaired skeletal muscle metabolic homoeostasis36. The gene discussed is SAV1; the disease is diabetes mellitus.